KOREAN DRUG CO., LTD.
Financials
Valuation Metrics
KOREAN DRUG CO., LTD.'s Market Cap is ₩374B. At end of 2025 it was ₩473B. Ranked #1946 of 2,421 in KR market (top 80%), #1221 of 1,640 on KOSDAQ (top 74%), #206 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 37.40B KRW | KR#1,946/2,421 Sec#206/231 |
| Revenue | 65.39B KRW | KR#1,650/2,421 Sec#107/231 |
| Net Income | 1.48B KRW | KR#1,449/2,421 Sec#99/231 |
| Total Assets | 94.32B KRW | KR#1,830/2,421 Sec#145/231 |
| Net Assets | 83.07B KRW | KR#1,558/2,421 Sec#125/231 |
| Employees | 172 | KR#1,205/2,421 Sec#100/231 |
| Value | ||
| P/E | 25.24x | KR#1,254/2,421 Sec#72/231 |
| P/B | 0.45x | KR#689/2,421 Sec#29/231 |
| P/S | 0.57x | KR#1,007/2,421 Sec#46/231 |
| EV/EBITDA | 4.22x | KR#161/2,421 Sec#3/231 |
| FCF Yield | 33.83% | KR#153/2,421 Sec#2/231 |
| Profitability | ||
| ROE | 1.78% | KR#1,423/2,421 Sec#98/231 |
| ROA | 1.57% | KR#1,296/2,421 Sec#92/231 |
| Op. Margin | 11.78% | KR#432/2,421 Sec#38/231 |
| Revenue Growth | 4.22% | KR#1,245/2,421 Sec#125/231 |
| Earnings Growth | -58.26% | KR#1,079/2,421 Sec#73/231 |
| Financial Health | ||
| Debt Ratio | 13.54% | KR#220/2,421 Sec#36/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 12.65B KRW | KR#649/2,421 Sec#37/231 |
| Cash | 4.89B KRW | KR#2,010/2,421 Sec#185/231 |
| Net Debt/EBITDA | -0.63x | KR#459/2,421 Sec#25/231 |
| Dividend | ||
| Div. Yield | 5.27% | KR#249/2,421 Sec#6/231 |
| Div. Growth | 12.50% | KR#544/2,421 Sec#30/231 |
| Performance | ||
| 1Y Return | -26.80% | KR#1,466/2,421 Sec#112/231 |
| 1M Return | 1.04% | KR#1,109/2,421 Sec#83/231 |
| From 52W High | -27.66% | KR#462/2,421 Sec#26/231 |
| 1Y MDD | -32.83% | KR#335/2,421 Sec#26/231 |
| Trading | ||
| Volume | 182 shares | KR#2,371/2,421 Sec#227/231 |
| Trading Value | 618,190 KRW | KR#2,378/2,421 Sec#228/231 |
| Foreign Own. | 2.84% | KR#1,339/2,421 Sec#121/231 |
| Per Share | ||
| EPS | 135 KRW | KR#1,381/2,421 Sec#91/231 |
| BPS | 7,552 KRW | KR#1,168/2,421 Sec#85/231 |
Company Info
Koryo Pharm, established in 1980, manufactures and sells pharmaceuticals, listing on the KOSDAQ market in 2000. The company produces and distributes over-the-counter drugs, including Haben, a leading cold medicine in Korea, along with professional pharmaceuticals for central nervous system diseases such as dementia and epilepsy. Committed to public health, it conducts research and development for new drugs and generics, with its R&D capabilities recognized through patent applications and technology certifications. Koryo Pharm is headquartered in Icheon, Gyeonggi-do.